title: Prevention and reversal of cerebral vasospasm by an endothelin-converting enzyme inhibitor, CGS 26303, in an experimental model of subarachnoid hemorrhage.
abstract: Delayed cerebral ischemia due to cerebral vasospasm is a major cause of morbidity and mortality in patients with aneurysmal subarachnoid hemorrhage (SAH). Increasing evidence implicates the potent vasoconstrictor peptide endothelin (ET) in the pathophysiology of cerebral vasospasm. In the present study the authors examined the therapeutic value of blocking the production of ET-1 by inhibiting the conversion of its relatively inactive precursor, Big ET-1, to a physiologically active form. An inhibitor of ET-converting enzyme (ECE), CGS 26303, was injected intravenously after inducing SAH in New Zealand white rabbits. Injections of CGS 26303 were initiated either 1 hour after SAH (prevention protocol) or 24 hours after SAH (reversal protocol). One of three concentrations (3, 10, or 30 mg/kg) of CGS 26303 was injected twice daily, and all animals were killed by perfusion fixation 48 hours after SAH occurred. Basilar arteries were removed and sectioned, and their cross-sectional areas were measured in a blind manner by using computer-assisted videomicroscopy. Treatment with CGS 26303 attenuated arterial narrowing after SAH in both the prevention and reversal protocols. The protective effect of CGS 26303 achieved statistical significance at all dosages in the prevention protocol and at 30 mg/kg in the reversal protocol. These findings demonstrate that inhibiting the conversion of Big ET-1 to ET-1 via intravenous administration of an ECE inhibitor can be an effective strategy for limiting angiographic vasospasm after SAH. Moreover, the results demonstrate that treatment with the ECE inhibitor is capable of reducing vasospasm even when initiated after the process of arterial narrowing has begun. Finally, the results provide further support for the role of ET in the establishment of cerebral vasospasm. The ECE inhibitor CGS 26303 thus represents a promising therapeutic agent for the treatment of cerebral vasospasm following aneurysmal SAH.
authors.affiliation: Department of Neurological Surgery, University of Virginia Health Sciences Center, Charlottesville 22908, USA.
authors.forename: A L
authors.initials: AL
authors.lastname: Kwan
authors.forename: M
authors.initials: M
authors.lastname: Bavbek
authors.forename: A Y
authors.initials: AY
authors.lastname: Jeng
authors.forename: W
authors.initials: W
authors.lastname: Maniara
authors.forename: T
authors.initials: T
authors.lastname: Toyoda
authors.forename: R W
authors.initials: RW
authors.lastname: Lappe
authors.forename: N F
authors.initials: NF
authors.lastname: Kassell
authors.forename: K S
authors.initials: KS
authors.lastname: Lee
mesh_terms: D000818:Animals; D004195:Disease Models, Animal; D002546:Ischemic Attack, Transient / Q000188:drug therapy* / Q000517:prevention & control*; D008297:Male; D063065:Organophosphonates / Q000494:pharmacology*; D011480:Protease Inhibitors / Q000494:pharmacology*; D011817:Rabbits; D013345:Subarachnoid Hemorrhage / Q000188:drug therapy*; D013777:Tetrazoles / Q000494:pharmacology*
chemical_list: D063065:Organophosphonates; D011480:Protease Inhibitors; D013777:Tetrazoles; C089987:CGS 26303